The primary endpoint was clinical remission at week @ , defined as MCS of @ or less ( with no individual subscore of > @ ) , analysed in the modified intention-to-treat population ( mITT ; all randomly assigned patients who had received at least one dose of study drug , had at least one post-baseline disease-activity assessment , and had a centrally read screening endoscopic subscore of @ ) .